GridAI Technologies Corp. (GRDX)
| Market Cap | 10.52M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 3.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 213,324 |
| Open | 2.800 |
| Previous Close | 2.850 |
| Day's Range | 2.790 - 3.340 |
| 52-Week Range | 1.920 - 5.300 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2025 |
About GRDX
GridAI Technologies Corp. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It serves residential and small... [Read more]
News
GridAI and the New Operating Reality of the Electric Grid
BOCA RATON, FL / ACCESS Newswire / January 14, 2026 / For decades, managing the electric grid was largely a planning exercise. Operators forecast demand, built capacity, and adjusted slowly as conditi...
GridAI's Role at the Center of Grid Intelligence Economics
BOCA RATON, FL / ACCESS Newswire / January 13, 2026 / Infrastructure narratives are easy to tell. Execution narratives are harder, and far more revealing.
GridAI and the Financial Mechanics of Grid Intelligence
BOCA RATON, FL / ACCESS Newswire / January 12, 2026 / Grid intelligence only matters if it changes cost structures, creates new revenue streams, or both. Otherwise, it's just another layer of software...
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at 1...
ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer
BOCA RATON, FLORIDA / ACCESS Newswire / November 19, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("Entero" or the "Company") today announced that its subsidiary Grid AI has executed a Letter of Int...
Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy
Timed with a sharp acceleration in AI-data-center expansion, with more than $60B in new projects announced in the last 90 days. BOCA RATON, FL / ACCESS Newswire / November 13, 2025 / Entero Therapeuti...
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid
Integration boosts Grid AI's deployment capacity as AI data-center power demand approaches 50 GW, growing by over 165% through 2030 i BOCA RATON, FL / ACCESS Newswire / November 6, 2025 / Entero Thera...
Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics (NASDAQ:ENTO) has just made one of the boldest moves in its history, a reinvention that trades long biotech timelines for imm...
Entero Regains Nasdaq Compliance With Grid AI Acquisition
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO) is pleased to announce that, as a result of the acquisition of 100% of Grid AI...
Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid
BOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) ("ENTO" or the "Company") a company pioneering innovation at the intersection of biotechnology and AI-driv...
From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)
BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ: ENTO) has reinvented itself in a way few public companies dare. By acquiring GRID AI , it has stepped directly into ...
Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It
BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) didn't tiptoe into reinvention. It jumped.
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus
U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.
ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy st...
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy st...
Entero Therapeutics, Inc. Announces Reverse Stock Split
Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of target...
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of target...
FluroTech Ltd. Announces Change in Directors
Calgary, Alberta--(Newsfile Corp. - June 13, 2025) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") is pleased to announce that effective June 12, 2025, Eric Corbett has been appointed t...
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the developmen...
Entero Therapeutics Appoints Richard Paolone as CEO
BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of ...
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or b...
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therape...
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
BOCA RATON, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), today announced that it has entered into a binding term sheet for a reverse me...
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune r...